Article Information
History
- August 31, 2023.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Author Information
- Dickran Kazandjian1,*,
- Benjamin Diamond1,*,
- Marios Papadimitriou1,
- Elizabeth Hill2,
- Romanos Sklavenitis-Pistofidis3,
- Bachisio Ziccheddu1,
- Patrick Blaney4,
- Monika Chojnacka1,
- Michael Durante1,
- Kylee Maclachlan5,
- Ryan Young2,
- Saad Usmani5,
- Faith Davies4,
- Gad Getz6,
- Irene Ghobrial3,
- Neha Korde5,
- Gareth Morgan4,#,
- Francesco Maura1,#,† and
- Ola Landgren1,#
- 1Myeloma Institute, Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL
- 2Myeloma Program, Lymphoid Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA
- 3Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA
- 4Myeloma Research Program, NYU Langone, Perlmutter Cancer Center, New York, NY
- 5Myeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY
- 6Broad Institute of MIT and Harvard, Cambridge, MA
- ↵†Corresponding author; email: fxm557{at}miami.edu
Posted August 31, 2023.
Genomic Profiling to Contextualize the Results of Intervention for High-Risk Smoldering Myeloma
